Liquidia Stock Plummets Nearly 50% After Adverse Patent Infringement Ruling

Shares of Liquidia Corporation (NASDAQ: LQDA) plummeted in recent trading after a federal court ruled the company had infringed on key patent claims held by rival United Therapeutics. The decision deals a significant blow to Liquidia's flagship product, YUTREPIA, and triggered multiple trading halts due to the stock's extreme volatility.

The Court's Decision

The U.S. District Court for the District of Delaware found that Liquidia infringed on two claims of United Therapeutics’ U.S. Patent No. 11,826,327. The court did, however, invalidate four other patent claims that United Therapeutics had asserted against Liquidia.

The infringed claims cover the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) using inhaled treprostinil, the active ingredient in YUTREPIA. This specific indication is critical for Liquidia, representing a substantial portion of the drug's target market.

Commercial and Market Impact

The commercial implications for Liquidia are severe. The company acknowledged that the PH-ILD indication accounts for approximately half of YUTREPIA's current market. In response to the ruling, Liquidia announced it will submit a supplement to the U.S. Food and Drug Administration (FDA) to remove that indication from the drug's label.

The stock's reaction was immediate and dramatic:

Ad

• Liquidia shares cratered 48.3% to close at $36.55.
• In contrast, shares of United Therapeutics (NASDAQ: UTHR) surged on the news, reflecting the zero-sum nature of the patent dispute.

Further uncertainty remains, as United Therapeutics has requested injunctive relief that could impose additional restrictions on YUTREPIA's availability. Both parties have one week to submit proposed remedies to the court, leaving the full financial exposure difficult to quantify.

Company Response and Outlook

Liquidia's CEO, Roger Jeffs, stated the company "respectfully disagree[s] with the Court’s decision" regarding the two infringed claims and is "fully prepared to pursue all available appellate options."

For investors, the adverse legal outcome upends market expectations, which had appeared to price in a more favorable result for Liquidia. The ruling now casts significant uncertainty over the future revenue potential of the company's most important asset.